Table 2.

Predictors of progression to castration-resistant disease in patients with bone metastatic prostate cancer.

	Univariate			Multivariatea
	HR	(95% CI)	P	HR	(95% CI)	P
Age (y)	0.991	(0.967–1.016)	0.471
BMI	1.027	(0.963–1.095)	0.422
Gleason score (≥8)	1.759	(1.068–2.898)	0.027
T stage (≥T3)	1.195	(0.484–2.947)	0.701
Baseline PSA	1.000	(0.998–1.001)	0.593
Time to PSA nadir	0.916	(0.859–0.977)	0.008	0.877	(0.812–0.947)	0.001
PSA nadir	1.000	(0.993–1.006)	0.931
PSA nadir maintenance period	0.968	(0.939–0.998)	0.041
PSA velocity	1.000	(1.000–1.000)	0.603
Baseline ALP	1.001	(1.001–1.002)	<0.001	1.001	(1.000–1.002)	0.007
VAS pain score (≥1)	1.519	(1.022–2.258)	0.039	3.061	(1.434–6.531)	0.004
ECOG PS (≥1)	1.141	(0.741–1.760)	0.552
Number of bone lesions	1.016	(0.997–1.036)	0.095

ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson Comorbidity Index; CI, confidence interval; CRPC, Castrate-resistance prostate cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; HR, hazards ratio; LN, lymph node; PSA, prostate-specific antigen; VAS, Visual Analogue Scale.

^aForward step-wise conditional method.